Biotech RadarJobs updated

COMPANY

MediciNova

HQ: La Jolla, CA source · medicinova.com ↗

Clinical Phase 3

Keywords: neurology respiratory liver diseases Amyotrophic Lateral Sclerosis Asthma Hypertriglyceridemia Non-Alcoholic Fatty Liver Disease Chronic Obstructive Pulmonary Disease Type 2 Diabetes Mellitus Idiopathic Pulmonary Fibrosis IPF Glioblastoma Recurrent Glioblastoma GBM Newly Diagnosed Glioblastoma Viral Pneumonia Non-alcoholic Steatohepatitis Hypercholesterolemia Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis Interstitial Cystitis Status Asthmaticus MN-166 MN-001 MN-221 Ibudilast

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

17Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia source ↗
  2. Trial start Phase 2: Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS source ↗
  3. Trial start Phase 2/Phase 3: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS source ↗
  4. Trial start Phase 1: Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers source ↗
  5. Trial start Phase 1/Phase 2: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma source ↗
  6. Trial start Phase 1: Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers source ↗
  7. Trial start Phase 1/Phase 2: A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) source ↗
  8. Trial start Phase 2: Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis source ↗
  9. Trial start Phase 2: Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects source ↗
  10. Trial start Phase 2: Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) source ↗
  11. Trial start Phase 2: Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis source ↗
  12. Trial start Phase 1: Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients source ↗
  13. Trial start Phase 1: Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) source ↗
  14. Trial start Phase 2: Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma source ↗
  15. Trial start Phase 2: Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma source ↗
  16. Trial start Phase 2: Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma source ↗
  17. Trial start II: Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT04057898Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSPhase 2/Phase 3Active, not recruitingMay 28, 20202027-04 (estimated)
NCT05464784MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaPhase 2Active, not recruitingAug 22, 2022Dec 31, 2026 (estimated)
NCT02503657Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisPhase 2CompletedMar 9, 2016Dec 7, 2020 (actual)
NCT03782415Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaPhase 1/Phase 2CompletedDec 29, 2018Aug 7, 2023 (actual)
NCT04429555Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSPhase 2CompletedJan 11, 2021Jun 30, 2022 (actual)
NCT02714036A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)Phase 1/Phase 2CompletedMay 6, 2016Dec 31, 2019 (actual)
NCT02681055Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsPhase 2Completed2016-03May 30, 2018 (actual)
NCT02238626Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)Phase 2Completed2014-092017-08 (actual)
NCT01982942Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisPhase 2Completed2013-112017-05 (actual)
NCT04054206Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersPhase 1CompletedJun 24, 2019Jul 17, 2019 (actual)
NCT03533387Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy VolunteersPhase 1CompletedApr 11, 2018Jul 6, 2018 (actual)
NCT01013142Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Phase 1Completed2009-112010-03 (actual)
NCT00838591Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of AsthmaPhase 2Completed2009-032012-03 (actual)
NCT01551316Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) PatientsPhase 1Completed2012-032012-05 (actual)
NCT00295854Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisIICompleted2005-052006-10 (actual)
NCT00679263Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe AsthmaPhase 2Completed2008-022008-07 (actual)
NCT00683449Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of AsthmaPhase 2Terminated2008-062009-03 (actual)
Feedback